Onxeo SA (Germany) Top Insiders
| C4X Stock | EUR 0.14 0.01 7.69% |
Onxeo SA employs about 25 people. The company is managed by 27 executives with a total tenure of roughly 231 years, averaging almost 8.0 years of service per executive, having 0.93 employees per reported executive. Examination of Onxeo SA's management performance can provide insight into the company performance.
| Judith Greciet CEO Chief Executive Officer, Member of the Executive Committee, Member of the Board |
| Joseph Zakrzewski Chairman Non-Executive Chairman of the Board |
Onxeo |
Onxeo SA Management Team Effectiveness
The company has return on total asset (ROA) of (0.1378) % which means that it has lost $0.1378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3184) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities. The Onxeo SA's current Non Currrent Assets Other is estimated to increase to about 31.3 M, while Total Assets are projected to decrease to roughly 15.3 M.The current Common Stock Shares Outstanding is estimated to decrease to about 103.8 M. The current Net Loss is estimated to decrease to about (7.2 M)Onxeo SA owns a total of 499.45 Million outstanding shares. Onxeo SA holds 9.4 pct. of its outstanding shares held by insiders and 8.8 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Onxeo SA in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Onxeo SA, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Onxeo SA Workforce Comparison
Onxeo SA is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2.22 Million. Onxeo SA adds roughly 25.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Onxeo SA Benchmark Summation
The output start index for this execution was one with a total number of output elements of sixty. The Lowest value over a specified period line plots minimum value of Onxeo SA price series.
Onxeo SA Notable Stakeholders
An Onxeo SA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Onxeo SA often face trade-offs trying to please all of them. Onxeo SA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Onxeo SA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Judith Greciet | Chief Executive Officer, Member of the Executive Committee, Member of the Board | Profile | |
| Joseph Zakrzewski | Non-Executive Chairman of the Board | Profile | |
| Julien Miara | CEO Chairman | Profile | |
| Michel Forest | Vice President Quality Qualified Person and Member of the Executive Committee | Profile | |
| Nicolas Fellman | Vice President, Chief Financial Officer, Member of the Executive Committee | Profile | |
| Louis Kayitalire | Vice President Head of Research & Development | Profile | |
| Philippe Maitre | Executive Vice President and Chief of U.S. Operations | Profile | |
| Elisabeth Carstensen | Director of Alliance Management, Member of the Executive Committee | Profile | |
| Caroline Lemarchand | Preclinical R&D Director, Member of the Executive Committee | Profile | |
| Sonia Vallons | Quality Assurance Director, Member of the Executive Committee | Profile | |
| Delphine Lucas | Regulatory Affairs Director, Member of the Executive Committee | Profile | |
| Audrey LegentilDumery | Director of Human Resources, Member of the Executive Committee | Profile | |
| Lucile Dez | Director Administration | Profile | |
| Aude Michel | Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | Profile | |
| Antoine Barouky | Deputy Director | Profile | |
| Russell Greig | Independent Member of the Board | Profile | |
| Huiping Jiang | Senior Assurance | Profile | |
| Thomas Hofstaetter | Independent Member of the Board | Profile | |
| MD MPH | CEO Pres | Profile | |
| Francoise Bono | Chief Scientific Officer, Member of the Executive Committee | Profile | |
| Nicolas Trebouta | Member of the Board - Permanent Representative of Financiere de la Montagne | Profile | |
| David Solomon | Independent Member of the Board | Profile | |
| Remi Droller | Member of the Board - Representative of Kurma Life Science Partners | Profile | |
| Daniele GuyotCaparros | Independent Member of the Board | Profile | |
| Olivier Beaumont | Chief Medical Officer, Member of the Executive Committee | Profile | |
| Wael Jdey | Head Preclinical | Profile | |
| Nicolas Fellmann | CFO Director | Profile |
About Onxeo SA Management Performance
The success or failure of an entity such as Onxeo SA often depends on how effective the management is. Onxeo SA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Onxeo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Onxeo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people.
Onxeo SA Workforce Analysis
Traditionally, organizations such as Onxeo SA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Onxeo SA within its industry.Onxeo SA Manpower Efficiency
Return on Onxeo SA Manpower
| Revenue Per Employee | 71.7K | |
| Revenue Per Executive | 66.4K | |
| Net Loss Per Employee | 957.2K | |
| Net Loss Per Executive | 886.3K |
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |